Good morning and welcome to the OraSure Technologies 2019 Annual Meeting of Stockholders. My name is Mike Solano, and I'm Chairman of the Board of Directors. I also serve on the company's audit and compensation committees. I was most recently the Chief Operating Officer of Recro Pharma, a specialty pharmaceutical company. I will be acting as Chairman of this meeting.
With me today are Steve Tang, OraSure's President and Chief Executive Officer and Roberto Cuca, Chief Financial Officer for the company. Steve is also a member of the Board. Jack Jarrett, OraSure's General Counsel is also here and will act as secretary of the meeting. We are pleased again to be conducting this meeting in a completely virtual format.
There are
several items of business that we should consider as explained in our proxy statement. Following these items, there will be a Q and A session during which stockholders attending the meeting may ask questions. Questions may be submitted by following the instructions on the website page for this meeting and the meeting notice sent to the stockholders. You may submit your questions now or at any time during the meeting. The only questions that are germane to the meeting being discussed in today's meeting will be for Starzitter.
As archived audio copy of the meeting will be available on the web page for the meeting approximately 24 hours after our meeting concludes and will remain available for a period of 7 business days thereafter. The specter of election for the meeting is Ms. Anna Tagberg of Broadridge Financial Solutions.
True. Yes.
Tagberg has taken a note that this will be included with the minutes of the meeting. Yes, definitely. Broadridge has also provided with an affidavit certifying that notice of this meeting was sent on April 10, 2019 to all stockholders of record as of March 28 record date. Notice of this meeting stockholders entitled to those of this meeting is available for inspection by any stockholder for any purpose to remain to this meeting. This list may be accessed on the website or according to both the company's records and a certificate of the inspector, there are 62,050,806 shares of the company's common stock entitled to vote at this meeting.
The inspectors determined that persons holding a majority of the outstanding shares of stock are attending this meeting by proxy. Accordingly, I declare that a quorum is present, and the 2019 Annual Meeting of Stockholders is now called to order. Before proceeding further, I would like to introduce the additional members of the company's Board of Directors. Each of these directors is also attending the meeting electronically. From the Board, we have Mara Aspinall, President and CEO of Health Catalyst, an investment advisory firm serving healthcare and technology companies.
Mara serves on the audit and compensation committees Eamon Hobbs, President of Hobbs Medical Ventures, a health care consulting company. Eamon is Chairman of our Nominating Corporate Governance Committee and also serves on the Compensation Committee Ronnie Lancaster, former Senior Vice President for Federal Government Relations of Assurant, Inc, a global provider of risk management solutions. Ronnie is Chairman of the Compensation Committee and serves on the Nominating and Corporate Governance Committee. Charles Patrick, Principal of Patrick Consulting, Chuck serves on the Audit and Nominating and Corporate Governance Committees. Aradha Sarind, Executive Vice President, Chief Strategy and Business Officer for Alexion Pharmaceuticals.
Alexion is a global biopharmaceutical company. Robin is Chairman of our Audit Committee and serves on the Nominating and Corporate Governance Committee. Finally, Joseph Kalinowski and Jennifer Strong from KPMG are also attending the meeting electronically. KPMG is the company's independent registered public accounting firm. The KPMG representatives are available to respond to questions raised during the Q and A session, if necessary.
Before proceeding with the formal agenda, I would like to make a few brief remarks about Orichor's performance during 2018. 2018 was not only a financial successful year, it was all strategically important for the company. Our consolidated net revenues in 2018 grew by 9% over the prior year and reached a new record level. We also continued to deliver strong profitability. Our international HIV business and our molecular business continued to drive performance with double digit revenue growth.
Our microbiome business revenue grew 92% year over year. We delivered these strong results while at the same time managing successful senior management transition. As you know, last year, Steve Tang became our CEO and Roberto Cuco joined the company as our CFO. We also completed an extensive review of our business that resulted in an updated long term strategy, focused on innovation and growth. Steve and his team wasted no time in aggressively implementing this new growth strategy.
After completing an intense period of due diligence and negotiation in the second half of twenty eighteen, we began 2019 with the closing of 2 strategic acquisitions early in the year. 1 of the companies we purchased, CoreBiome, is a microbiome laboratory service provider and the other, Novosanis, manufactures and sells an innovation and innovative collection kit designed to collect 1st void urine samples. These new members of our corporate family are adding new products and technologies and new market reach for our business. We believe these new affiliates will become strong growth contributors in the years to come. So with the new leadership in place, a newly updated long term strategy and 2 recent acquisitions, we are pleased with the state of our business and our future prospects.
We're optimistic about our expected 2019 full year performance despite the impact of a large customer, a consumer Genovis customer changing its business plans. We continue to diversify our molecular collections business and are seeing opportunities in other parts of the genomics market. We are confident in our management and business strategy, and we believe we are on the right track continue executing against our strategy and deliver long term value to our shareholders. With that, I will now move into the formal part of our stockholder meeting. The order of business will be set forth in a proxy statement.
Copy of the agenda is available on the website for this meeting. The business transacted today will be limited to 3 items. The polls are open for voting. By following the directions on the website and in the meeting notice sent to our stockholders. After all business items have been discussed, I will close the polls and no further voting will be permitted.
As indicated in the agenda, the first item of business is the election of 2 Class I Directors. The Board nominees are Stephen Tang and Eamon Hobbs. The Class 1 Directors elected today will hold office until the company's annual meeting in the year 2022. Each nominee is presently a director of the company and has consented to serve if elected. The names of the Director's nominees have been placed at the nomination.
Additional information about each nominee can be found in our proxy statement. No other nominations were made in accordance with the procedures established by the company's bylaws. Quarterly, the nominations have been closed. The company's Board of Directors is recommending the stockholders vote for the director nominees. The second item of business is the ratification of the appointment of KPMG LLP as the company's independent registered public accounting firm for 2019.
KPMG has served in this capacity for the past several years. The deployment of KPMG has been approved by the audit committee and Board and the Board is recommending that stockholders vote for ratification of KPMG's appointment. The 3rd item of business is the approval by a non binding advisory vote of the compensation of the company's named executive officers as disclosed in our proxy statement. Federal law requires that we provide stockholders with the opportunity to vote on the compensation paid to the executives. This is competently referred to as say on pay vote.
Setting appropriate levels of executive compensation is important issue and one we take very seriously. We believe our executive compensation for 2018 is competitive and fully aligned with our pay for performance philosophy. Accordingly, the Board is recommending the stockholders vote for approval of the resolution on executive compensation as set forth in the proxy statement. The polls will be closed momentarily, so if you had not done so yet, please cast your vote at this time. Stockholders desiring to vote have now had an opportunity to vote their shares either prior to today or during this meeting.
Accordingly, I declare that the polls are closed. I ask that the inspector tally the votes and prepare a certificate of results. There being no further business to conduct, the formal portion of the meeting is now adjourned. In the time remaining, we will answer questions if there are any. There does not appear to be any questions.
I will now conclude the Q and A session. Before ending the webcast, I'd like to provide a preliminary report on the voting as prepared by the inspector. Taking into account the number of shares represented at the meeting, the tabulation of all the proxies and ballots indicate that on a preliminary basis, the nominees for the Board have been reelected, the appointment of KPMG has been ratified and the compensation of the company's named executive officers as described in the proxy statement has been approved. A written certificate of the final vote for each of these items will be prepared by the inspected and filed with the minutes for this meeting. These results will also be disclosed by the company in an upcoming SEC filing.
That's all we have for today. On behalf of the company and the Board, I'd like to thank all of the stockholders for your continued support and for your participation in this year's meeting.
Ladies and gentlemen, the conference has now concluded. We thank you for attending today's presentation. You may now disconnect your lines.